Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use (FALLA)
Clinical Outcomes,Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab. A Multicenter Post-Marketing Observational Study in Routine Clinical Use
This is a prospective, single-arm, post marketing observational study in adult patients with active rheumatoid arthritis (RA) who are discontinuing treatment due to lack of efficacy, intolerance or to an incomplete response with either infliximab or etanercept.
The aim of this post-marketing observational study is to obtain data on clinical outcomes, compliance and tolerability to determine the effectiveness of switching from infliximab or etanercept to adalimumab. In this cohort, the different treatment strategies are to be studied in the context of the routine clinical practice in the different participating places.
研究概览
地位
条件
详细说明
This is a prospective, single-arm, post marketing observational study in adult patients with active RA who are discontinuing treatment due to lack of efficacy, intolerance or to an incomplete response with either infliximab or etanercept.
The aim of this post-marketing observational study is to obtain data on clinical outcomes, compliance and tolerability to determine the effectiveness of switching from infliximab or etanercept to Adalimumab. In this cohort, the different treatment strategies are to be studied in the context of the routine clinical practice in the different participating places.
Study Objectives:
Primary objective:
To assess the effectiveness of the treatment with adalimumab in patients with rheumatoid arthritis (RA) that have failed or presented an incomplete response to current treatment with either infliximab or etanercept.
Secondary objective:
To evaluate the compliance and clinical tolerability with adalimumab
Investigational Plan and Selection of Study Population:
All patients belonging to any of the centres participating in the study that meet all the inclusion criteria and none of the exclusion criteria will be considered eligible.
Patients considered eligible for the study will have to give their consent for the use and/or disclose of the patient's personal and/or health data. Patient's consent will be obtained before his/her participation in the study and will be documented in an Informed Consent Form approved by an Ethics Committee.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Chihuahua、墨西哥、31000
- Site Reference ID/Investigator# 27882
-
Chihuahua、墨西哥、31200
- Site Reference ID/Investigator# 27883
-
Culiacán Sin.、墨西哥、80000
- Site Reference ID/Investigator# 27884
-
Guadalajara, Jal.、墨西哥、44320
- Site Reference ID/Investigator# 27888
-
Guadalajara, Jal.、墨西哥、44650
- Site Reference ID/Investigator# 27886
-
Guadalajara, Jal.、墨西哥、44670
- Site Reference ID/Investigator# 27887
-
Leon, Gto.、墨西哥、37000
- Site Reference ID/Investigator# 25943
-
Mexico City、墨西哥、03100
- Site Reference ID/Investigator# 28059
-
Mexico City,、墨西哥、06700
- Site Reference ID/Investigator# 27885
-
Puebla, Pue.、墨西哥、72000
- Site Reference ID/Investigator# 27890
-
Puebla, Pue.、墨西哥、72570
- Site Reference ID/Investigator# 27889
-
Tuxtla Gutierrez、墨西哥、29000
- Site Reference ID/Investigator# 28057
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Patients ≥18 and <75 years of age that meet the American College of Rheumatology (ACR) criteria for RA.
Patients with active RA defined as:
- ≥3 tender joints and ≥3 swollen joints, or
- DAS 28 score >3.1
Patients who are discontinuing treatment with either infliximab or etanercept due to:
- Lack of efficacy, or
- Incomplete response.
- Patients that, in the opinion of the physician could result beneficiated with the locally approved treatment scheme of adalimumab
- Those patients who switch from infliximab or etanercept to adalimumab has been done in the last 60 days could be included in the study.
Exclusion Criteria:
The following patients will not be included in the study:
- Patients who have active infections.
- Patients with latent TB. For this protocol, evidence of latent TB infection is defined as an induration (not erythema) of 5 mm or greater, 48-72 hrs after placement. Any suggested data on the clinical history or chest x-ray.
- Patients participating into another study or clinical trial
- Any condition that according to the criteria of the participating physician represents an obstacle for study conduct and/or represents a potential unacceptable risk for patients.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
---|
Non responders to other anti-TNF
Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers.
A 40 mg dose was administered every other week for 24 weeks.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
DAS28 (Disease Activity Score in 28 Joints)
大体时间:Baseline and Weeks 8,16 and 24
|
The DAS 28 index measures disease activity in rheumatoid arthritis and is derived from the number swollen/tender joints, laboratory tests of inflammation, and participant assessment of global health (by marking a 10 cm line from "very good" to "very bad").
Ranges were used to classify participants, with a higher score indicating worse control of disease: Remission (<= 2.6), Low Disease Activity (>2.6 to <=3.2), Moderate Disease Activity (>3.2 to <= 5.1) and High Disease Activity (>5.1).
The mean change in DAS 28 score from baseline to each visit is presented.
|
Baseline and Weeks 8,16 and 24
|
Tender Joint Count and Swollen Joint Count
大体时间:Baseline and Weeks 8,16 and 24
|
The treating physician was to clinically assess each participant at each study visit and report the number of tender and swollen joints.
The mean number of painful or swollen joints for participants evaluated at each time point are presented.
|
Baseline and Weeks 8,16 and 24
|
Severity of Pain in a 100mm Visual Analogue Scale (VAS 100mm)
大体时间:Baseline and Weeks 8,16 and 24
|
Participants assessed the severity of their pain using a 0 to 100 mm horizontal visual analogue scale (VAS).
The far left end indicated no pain (0 mm) and the far right meant the worst possible pain (100 mm).
Participants drew a vertical line on the horizontal scale to indicate their current level of pain at each visit.
|
Baseline and Weeks 8,16 and 24
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Evaluate the Compliance and Clinical Tolerability With Adalimumab
大体时间:Baseline to Week 24
|
To assess compliance, participants were asked at the Week 8 and Week 16 visits how many doses they had missed since their previous visit.
Adverse events were collected throughout the study, from the time the participant signed the informed consent form until 30 days or 5 half-lives after the last dose of study drug.
For additional information see the Reported Adverse Event section.
|
Baseline to Week 24
|
合作者和调查者
赞助
调查人员
- 学习椅:Juan Pozos, MD、Abbott
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.